Trial
NCT00422201
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
HRA Pharma
Collaborators
—
Condition
Cushing's Syndrome
Intervention
Mifepristone
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-11